Related Experiment Video
Updated: Jun 23, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Malignant melanoma therapy by chemotherapy and autoimmunity induced by cytokine
Shi Jin1, QingYuan Zhang, XinMei Kang
1Department of Oncology, The Third College Hospital of Harbin Medical University, Harbin, People's Republic of China.
Purpose:
The aim of this study was to evaluate the effect of combining dacarbazine (DTIC) and granulocyte/macrophage colony-stimulating factor (GM-CSF) with interleukin-2 (IL-2) in patients with advanced malignant melanoma.
Methods:
Twenty-seven (27) patients with advanced malignant melanoma received dacarbazine (500 mg/m(2)/days 1-2, intravenously), GM-CSF (175 ug/m(2)/days 3-6, subcutaneously), and interleukin-2 (400 MIU/m(2)/days 7-10, subcutaneously). Each treatment cycle required 21 days to completion.
Results:
Time to progression was 7-11 months. The total effective rate was 44.4%, and the combination of chemotherapy, GM-CSF, and IL-2 had low toxicity.
Conclusions:
The combination of DTIC with GM-CSF and IL-2 is feasible and possibly efficacious for clinical use.
More Related Videos
Related Concept Videos
Tumor Immunotherapy
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune system...
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
The Tumor Microenvironment
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Type I Diabetes II: Pathophysiology
